Delayed CINV (chemotherapy-induced nausea and vomiting) is experienced by up to 40% of cancer patients who receive emetogenic chemotherapy as a standard of care, especially for common colon, lung, breast, ovarian, and head and neck cancers. Nausea is the side effect most feared by cancer patients, but it is a subjective symptom with no objective measurement to predict or monitor. No real-time methods have been made available to monitor the core metabolic system that influences the occurrence of delayed CINV in individual patients.
Delayed CINV cases increase emergency room visits and strongly influence a patient’s overall health and social life, negatively impacting family, work and treatment adherence. While use of anti-emetic drugs has improved care, delayed CINV still affects many who receive emetogenic chemotherapy.
A multidisciplinary team of LIMR scientists and oncologists created a new proprietary blood test, called MyNauseaRisk test, that monitors a cancer patient’s core metabolic system and can identify those who are at high risk for delayed CINV. This test is predictive before chemotherapy is administered, enabling appropriate prophylactic care beforehand.
The global market for CINV was valued at US $1.67B in 2015 and is expected to reach $2.66B by 2022, according to the market information resource Allied Market Research.
LIMR’s technology detects a naturally occurring variation among individuals in the glutathione recycling efficiency in red blood cells, which the LIMR team discovered is correlated with the incidence of patient-reported delayed CINV.
Since this metabolic marker is intrinsic to a patient's physiology, its measurement before chemotherapy is administered can enable an oncologist to tailor more effective prophylactic care for those identified as high-risk individuals.
Stage of development
- An ongoing clinical trial with four participating medical oncologists at the Lankenau Cancer Center, which is one of only 46 NCI-designated U.S. community cancer centers that treats more than 1,000 analytic cancer cases annually (200 of whom were recruited to the MyNauseaRisk trial since 2016).
- A validated laboratory test with more than 80% specificity to detect delayed CINV, offering more accuracy than existing clinical algorithms to predict this condition.
- A published study of more than 60 patients completed in 18 months offering initial proof of concept in lung and colon cancer patients receiving platinum-based highly emetogenic chemotherapy.
MyNauseaRisk test kit: U.S. Patent No. 9,766,226 (issued Sept 19, 2017).
Clinical trials to identify patients at risk of delayed nausea as a tool to focus novel anti-emetic strategies on the population of interest. LIMR has outlicensed the technology to MYNARI Biomedical, Fort Washington, PA.
- McCourt DD, Parikh K, Brady AL, … Wallon UM, et al. (2019). The quest for reliable prediction of chemotherapy-induced delayed nausea among breast cancer patients. Journal of Unexplored Medical Data 4:6.
- Kutner T, Kunkel E, Wang Y, George K, Zeger EL, Ali ZA, Prendergast GC, Gilman PB and Wallon UM. (2017). Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea. Support Care Cancer 25:581-87.
- Li J, Zhang D, Jefferson PA, Ward KM and Ayene IS. (2014). A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds. J Pharmcol Toxicol Methods 69:39.
Institutional contact: George C. Prendergast, PhD, LIMR President and CEO, 484.476.8475, email@example.com
IP manager contact: Heather Rose, PhD, JD, VP of Technology Licensing and Startups, Thomas Jefferson University, 215.503.0770, firstname.lastname@example.org